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Catecholaminergic polymorphic ventricular tachycardia (CPVT) is induced by emotions or exercise in patients
without organic heart disease and may be polymorphic or bidirectional in nature. The prognosis of CPVT is
not good, and therefore prevention of sudden death is of utmost importance. Genetic variants of CPVT include
RyR2, CASQ2, CALM2, TRD, and possibly KCNJ2 and ANK2 gene mutations. Hypotheses that suggest the causes
of CPVT include weakened binding of FKBP12.6 and RyR2, a store overload-induced Ca2þ release (SOICR),
unzipping of intramolecular domain interactions in RyR2, and molecular and functional abnormalities caused
by mutations in the CASQ2 gene. The incidence of an RyR2 anomaly in CPVTs is about 35–79%, whereas
anomalies in the CASQ2 gene account for 3–5% CPVTs. The ping-pong theory, suggesting that reciprocating
delayed after depolarization induces bigeminy of the right and left bundle branches, may explain the
pathogenesis of bidirectional ventricular tachycardia. Flecainide, carvedilol, left sympathetic nerve denerva-
tion, and catheter ablation of the PVC may serve as new therapeutic strategies for CPVT while gene-therapy
may be applied to some types of CPVT in the future. Although, not all sudden cardiac deaths in CPVT patients
are currently preventable, new medical and interventional therapies may improve CPVT prognosis.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC
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1.1. Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
is induced by emotional stress or exercise in patients without
organic heart disease and may be polymorphic or bidirectionalopen access article under the CC BY-NC-ND license
Fig. 1. Typical features of ventricular tachycardia in a patient with CPVT. (A) Polymorphic ventricular tachycardia. (B) Bidirectional ventricular tachycardia. (C) Rapid poly-
morphic ventricular tachycardia deteriorating into ventricular ﬁbrillation. These electrocardiograms were recorded by Holter monitoring in the CM3 lead in the same patient.
Fig. 2. Surface representations of RyR2 3D reconstructions with and without bound
FKBP12.6. [7]. (A) High activity state of RyR2. A 3D map of RyR2, obtained by in vitro
assembly of puriﬁed RyR2 incubated with FKBP12.6 alone. (B) Low activity state of
RyR2. A 3D map of RyR2, obtained by incubating RyR2 with FKBP12.6 and an excess
of FK506. FKBP12.6 is denoted by the blue dots. The major difference in these
structures is observed in domain 6, which extends in the vertical direction (shown
by the blue arrow), and the transmembrane assembly is rotated about 4° (shown by
the blue arrow in the lower center panel). FKBP12.6: calstabin2, protein kinase A:
PKA, phosphatase 1: PP1, phosphatase 2A: PP2A, phosphodiesterase 4D3: PDE 4D3,
TA: transmembrane assembly.
N. Sumitomo / Journal of Arrhythmia 32 (2016) 344–351 345(Fig. 1) [1–3]. This ventricular arrhythmia sometimes degenerates
into rapid polymorphic ventricular tachycardia and ventricular
ﬁbrillation (Fig. 1) and may lead to syncope or sudden death. The
incidence of CPVT is reported to be as high as 1:10,000, but its real
prevalence is unclear.2. Clinical manifestations and prognosis
The ﬁrst clinical manifestations of CPVT are syncope or aborted
sudden cardiac death during exercise or emotional stress and
appear during the ﬁrst or second decade of life [1–3]. CPVT differs
from seizures, in that almost all syncopal events are associated
with physical activity or emotional stress and do not occur during
a resting state.
The prognosis of CPVT is very poor. About 40% patients die
within 10 years of diagnosis [3]. Although prognosis in recent timescould be better than previous reports, sudden death and severe
brain damage are still reported in CPVT patients.3. Diagnosis of CPVT
CPVT patients usually have a normal resting ECG, or just a lower
heart rate than is normal for their age [3]. During exercise in these
patients, monomorphic premature ventricular contractions (PVCs)
increase, then polymorphic, or bidirectional PVC bigeminy appear,
followed by bidirectional or polymorphic VT. Exercise induced
supraventricular arrhythmias (atrial ﬁbrillation, premature atrial
contraction, and atrial tachycardia) are also common in the patients
with CPVT [4]. The diagnostic criteria of CPVT are as follows [5]:
1. CPVT is diagnosed in the presence of a structurally normal
heart, normal ECG, and unexplained exercise or catecholamine-
induced bidirectional VT, polymorphic ventricular premature
beats or VT in individuals o40 years of age.
2. CPVT is diagnosed in patients (index case or family member)
who have a pathogenic mutation.
3. CPVT is diagnosed in family members of a CPVT index case with
a normal heart who manifests exercise-induced PVCs or bidir-
ectional/polymorphic VT.
4. CPVT can be diagnosed in the presence of a structurally normal
heart and coronary arteries, normal ECG, and unexplained exercise
or catecholamine-induced bidirectional VT, polymorphic ventricu-
lar premature beats or VT in individuals 440 years of age.4. Mechanism of CPVT
Themajor pathogenic mechanism of CPVT is thought to involve the
malfunction of RyR2. RyR2 is a large tetrameric protein expressed on
the sarcoplasmic reticulum (SR) membrane. RyR2 is anchored to cal-
sequestrin (CASQ2) by satellite proteins such as calmodulin (CaM),
FKBP12.6, (calstabin2), protein kinase A (PKA), phosphatase 1 (PP1),
and phosphatase 2A (PP2A) bound to the cytoplasmic region and
junction, and triadin (TRD) bound to the luminal side [6].
Fig. 3. FKBP12.6 dissociation from mutant RyR2 in the pathogenesis of CPVT [8]. FKBP12.6 acts as a stabilizer that preserves the closed RyR2 channel during diastole.
Weakened binding afﬁnity with FKBP12.6 may lead to a Ca2þ leak during diastole.
Fig. 4. The store overload-induced Ca2þ release (SOICR) hypothesis [8]. With normal RyR2, the resting and stress levels of free calcium are below the SOICR threshold (panel
A). If the SOICR threshold falls below the level of free SR calcium as with mutant RyR2, a leak of Ca2þ will occur and generate a delayed after-depolarization.
N. Sumitomo / Journal of Arrhythmia 32 (2016) 344–351346A three-dimensional reconstruction of RyR2 bound to FKBP12.6
is shown in Fig. 2B. When RyR2 is bound to FKBP12.6, it forms a
stable structure with closed pores, the domain 6 of RyR2 was
found to protrude into the luminal side, when observed from the
junctional face after the transmembrane assembly (TA) was rota-
ted counterclockwise by about 4° [7]. When unbound to FKBP12.6,
RyR2 assumes an open state (Fig. 2A) [7].
Several pathogenic hypotheses have been reported regarding
the causes of CPVT [8]. The ﬁrst theory suggests the dissociation of
FKBP12.6 from RyR2. The normal RyR2 channel is stabilized by
FKBP12.6 and closes during diastole. With mutant RyR2, the
binding afﬁnity with FKBP12.6 is weakened, and phosphorylation
of RyR2 by protein kinase A (PKA) results in dissociation ofFKBP12.6 from RyR2, resulting in open channels which may leak
Ca2þ during diastole (Fig. 3).
The second hypothesis is a store overload-induced Ca2þ release
(SOICR) theory [8]. With normal RyR2, the resting and stress levels
of free Ca2þ are below the SOICR level. However, with mutant
RyR2, the SOICR threshold drops below the level of free Ca2þ in
the SR. This may cause a spillover of Ca2þ from the SR (Fig. 4).
The third hypothesis considers defective intramolecular domain
interaction [8]. RyR2 is stabilized by a tight zipping of the intramo-
lecular structure. If a mutation interferes with this zipping structure,
the intramolecular domain interaction is weakened, causing an
unzipping of the interdomain structure and leads leaking of Ca2þ
from the SR (Fig. 5).
N. Sumitomo / Journal of Arrhythmia 32 (2016) 344–351 347The fourth hypothesis suggests that the molecular and func-
tional abnormalities are related to mutations in the CASQ2 gene
[8]. CASQ2 is a Ca2þ storage protein inside the SR. The functional
storage capacity of CASQ2 or its reduced levels, may lead to
increased levels of free Ca2þ inside the SR, leading to a Ca2þ leakFig. 5. Defective intramolecular domain interactions in RyR2 mutations [8]. The N
terminal domain and the central domain of RyR2 interact with a tight “zipping”
that serves to stabilize the channel (left panel). A mutation in either domain
weakens this interaction (unzipping), which results in leaking of Ca2þ from RyR2
(right panel).
Fig. 6. Molecular and functional abnormalities related to mutations in the CASQ2
gene [8]. Storage of Ca2þ in the SR largely depends on the level and function of
CASQ2 (upper panel). Decreased levels or function of CASQ2 results in increase in





CPVT1 CPVT2 CPVT3 CPVT4
Incidence (%) 50–60 1 {1 {1
Inheritance AD AR AR AD
Onset of symptoms 10 years 7 years 10 years 4 years
Sex M:F¼1:1 M:F¼1:1 M:F¼1:1 M:F¼1:1
Chromosome locus 1q43 1p13.1 7p22–p14 14q32.11
Gene RyR2 CASQ2 ? CALM1
Protein CaM
Sudden death (%) E10 E42 E75 E18during diastole (Fig. 6). It is also known that CASQ2 stabilizes
binding of RyR2 with TRD and the junction.
This Ca2þ overload activates the forward mode of the Naþ/Caþ
exchanger (NCX), increases the transient inward current (Iti), and
induces ventricular arrhythmias due to delayed after depolarizations
(DADs).5. Subtypes of CPVT
Several subtypes of CPVT have been reported (Table 1). The most
common type of CPVT is caused by an anomaly in the RyR2 gene
(CPVT1) [9,10]. This accounts for more than 50% of CPVT cases. In
our CPVT cohort, about 79% of the CPVT cases were related to an
anomaly in the RyR2 gene. The inheritance of CPVT1 is autonomic
dominant, and sudden death was observed in about 10% of these
patients. There were no sex differences noted in this CPVT.
The second most common type of CPVT is caused by a CASQ2
gene anomaly (CPVT2) [11,12]. The inheritance of CPVT2 is auto-
somal recessive, and the rate of sudden death is higher than that
observed in CPVT1. However, autosomal dominant mutations of
CASQ2 are also reported [13–15].
CPVT3 was reported in a family with showing a 7p22-p14
chromosome anomaly, but the gene responsible has not been
identiﬁed yet [16]. Recently, calmodulin (CALM) [17] and triadin
(TRD) [18] anomalies have been found to responsible for CPVT4
and CPVT5, respectively.
CALM is a protein that involves the calcium dependent ICa
inactivation of the L-type Ca channel. Further, CALM also stabilizes
the RyR2 channel. Thus, a mutation in CALMmay easily cause Ca2þ
overload. TRD is a protein that connects CASQ to RyR2, and stabi-
lizes the RyR2 channel. A mutation in TRD may also result in a
diastolic leak of Ca2þ and Ca2þ overload in the myocytes.
KCNJ2 encodes the cardiac inward rectiﬁer K channel. A muta-
tion in KCNJ2 causes the Andersen–Tawil syndrome (LQT7), and is
also reported in patients with exercise induced bi-directional VT
[19]. Whether or not this type of mutation should be included as a
subtype of CPVT is a matter of controversy. Mutations in the ANK2
gene are well known as a cause of LQT4. Recently, a patient with
an ANK2 mutation was reported to have bi-directional VT [20].
This may be another disease related to CPVT.
A type of adult CPVT has also been reported [21,22]. In this
disease, the patients are predominantly female, with CPVT onset at
the age of around 40 years, and no sudden death is reported. We
believe that this may not be a speciﬁc type of CPVT, but rather a
mild form of the disease.
In the Japanese CPVT registry, 78 patients (M:F¼26:52, age¼
11.278.2 years) were enrolled. In this registry, only 6% of the cases
were familial cases whereas 94% of the cases were sporadicAdult type
CPVT5 CPVT related diseases
ATS LQT4
{1 {1 {1 E30
Sporadic AD AD Sporadic
2, 26 years 14, 9, 17 years ? 420 years (40 years)
M¼3 F4M? ? FcM
6q22.31 17q24.3 4q25-26 　
TRD KCNJ2 ANK2 RyR2E30%
Kir2.1α Ankyrin-B
E25 ? ? 0
Fig. 7. Family history and gene anomalies in the Japanese registry. (A) Family history in the registry. (B) Gene mutations ND; gene testing was not performed.
Fig. 8. A possible mechanism for bidirectional ventricular tachycardia: ping-pong in the His–Purkinje system [27]. (A) Comparison of simulated rabbit ventricular (dashed
line) and Purkinje (solid line) action potentials (APs) and Cai transients during pacing at 600 ms. (B) Rate dependence of delayed after depolarizations (DADs) and bigeminy
in Purkinje cell AP models. For the green trace, the rate threshold for DAD-induced bigeminy was 67 bpm (pacing cycle length [PCL] 900 ms), such that pacing (black arrows)
at both 900 and 600 ms induced bigeminy. For the purple trace, the bigeminy rate threshold was 100 bpm (PCL 600 ms), such that pacing at 600 ms, but not 900 ms, induced
bigeminy. LBB: left bundle branch; RBB: right bundle branch. (C) Voltage snapshots depicting the activation sequence at BVT onset Beat #2 is the last paced beat, with normal
activation. Beat #3 is the ﬁrst beat of BVT, due to a DAD-triggered action potential (AP) arising in the right bundle branch (RBB), resulting in QRS with a left bundle branch
(LBB) block pattern. Beat #4 is the second beat of BVT, due to a DAD-triggered AP arising in the LBB and results in a QRS with RBB block pattern. Traces on the right show the
timing of APs recorded from the His bundle (red), RBB (green), and LBB (purple). (D) Computed ECG from the simulation in A, showing BVT. (E) ECG recorded in a patient
during BVT.
N. Sumitomo / Journal of Arrhythmia 32 (2016) 344–351348(Fig. 7A). In this cohort, 56% of the patients had not undergone
genetic testing. However, of the 46% patients who underwent
genetic testing, 79% of the patients had an RyR2 gene anomaly, 6%
had a CASQ2 gene anomaly, and in 15% of the patients the speciﬁc
causative gene anomaly was unknown (Fig. 7B). The estimated
RyR2 genotype percentage is reported to range from 35% [23] up to65% [24,25], and the CASQ2 genotyped patients are estimated to
account for approximately 3–5% [25].
The proportions of familial cases reported in other studies were
21.3% [26] and 30% [21]. The lower percentage of familial cases
observed in our cohort may be because half of the registered cases
are over 15 years old, at which time only information of familial
Fig. 9. Kaplan–Meier curve of cumulative survival to a ﬁrst major cardiac event before and after left cardiac sympathetic denervation (LCSD) in symptomatic patients with
CPVT [38]. In 63 patients with CPVT, the cumulated event free survival signiﬁcantly improved after LCSD.
Fig. 10. Pace mapping of PVC in a patient with CPVT [43]. (A) A perfect pace map of the second beat of the CPVT was obtained on the left ventricular septum. Purkinje
potential at that point was recorded during the PVC and sinus rhythm. (B) A perfect pace map of the ﬁrst beat of a PVC was obtained at the left coronary cusp. A discrete pre-
potential was recorded during the PVC, and a delayed potential was recorded during sinus rhythm.
N. Sumitomo / Journal of Arrhythmia 32 (2016) 344–351 349history was taken without exercise or genetic testing. This may
result in an apparently lower percentage of familial cases. Kawa-
mura et al. have reported that RyR2 positive CPVT cases are more
likely to have clinically diagnosed CPVT-affected family members
with bidirectional VT, and sinus bradycardia [26].6. The mechanism of bidirectional VT
Bidirectional VT is the most characteristic feature of CPVT. In
the His–Purkinje system, DAD induced bigeminy may differ
depending on whether they are induced by the right bundle
branch or the left bundle branch. The right bundle branch (RBB)
caused a DAD induced bigeminy at a pacing rate of 900 ms
(Fig. 8B), whereas the left bundle branch (LBB) induced a bigeminy
at a pacing rate of 600 ms (Fig. 8B) [27]. In these situations, the
sinus rate exceeded the threshold of the RBB-DAD induced bige-
miny rate, and the beat after the sinus beat may have been
induced from the RBB, resulting in a LBB block (LBBB) type PVC.
The coupling interval of the normal sinus beat to the LBBB type
PVC exceeded the threshold of the LBB-DAD induced bigeminy,
and the next beat arose from LBB, resulting in a RBB block (RBBB)
type PVC. When the coupling interval of the LBBB type PVC and
RBBB type PVC exceeded the threshold of the RBBDAD induced
bigeminy, the next beat arose from the RBB followed by a beatfrom the LBB, one after the other (Fig. 8C) [27]. This computer
simulation suggests a mechanism for the bidirectional VT.7. Therapy for the CPVT
7.1. β Blockers
The long acting β blocker, nadolol, is preferred for prophylactic
treatment of CPVT. Propranolol is also an effective medication.
However, β blockers cannot completely suppress the arrhythmic
events in CPVT patients [28].
Carvedilol is reported to inhibit the SOICR in an HEK 293 cell
culture model. Among various β blockers, only carvedilol inhibits
RyR2 activity [29]. Thus, carvedilol may be an effective β blocker
for CPVT, but its β blocking effect may be weak in comparison to
the other β blockers. Therefore, the efﬁcacy of carvedilol needs to
be further investigated.
7.2. Verapamil
Verapamil has also shown beneﬁcial effects in some CPVT
patients [30,31]. However, the long-term efﬁcacy of verapamil is
still controversial.
N. Sumitomo / Journal of Arrhythmia 32 (2016) 344–3513507.3. Flecainide
Flecainide is an effective medication for CPVT [32–34]. Flecai-
nide treatment shows improvement of ventricular arrhythmias in
74% of the genotype positive CPVT cases [32], and in 92% of the
genotype negative CPVT cases [34]. Flecainide is thought to func-
tion by direct suppression of the RyR2 receptor. Among the Class I
anti-arrhythmic medications, only ﬂecainide and propafenone
inhibit RyR2 activity [35]. However, recent report denies the direct
suppression of RyR2 by ﬂecainide [36]. That may suggest another
mechanism of ﬂecainide, such as inhibition of NCX.7.4. Left cardiac sympathetic denervation
Left cardiac sympathetic denervation is reported to be a useful
therapeutic method for suppressing ventricular arrhythmias in
CPVT patients [37,38]. In patients with uncontrollable ventricular
arrhythmias, left cardiac sympathetic denervation is highly useful
in controlling ventricular tachyarrhythmias (Fig. 9). The rate of
complications involving Horner syndrome is very low if denerva-
tion is performed in the lower half of the T1 sympathetic ganglion
through the T4 ganglion [38].
7.5. ICD
Implantation of an ICD should be considered in patients in the
absence of controlled optimal therapy [39]. However, implantation
of an ICD in children still has a number of technical problems [40].
Moreover, inappropriate or painful shocks may increase the risk of
further ventricular arrhythmias, and electrical storms that may
result in lethal events.7.6. Catheter ablation
Pulmonary vein isolation is reported to be effective in some
CPVT patients with atrial ﬁbrillation [41]. Purkinje cells are
reported to be more arrhythmogenic than ventricular myocytes in
a mutant knockout mouse model of CPVT [42]. The onset of CPVT
may be initiated from Purkinje cells. Successful catheter ablation
has been reported at the site of Purkinje potentials or discrete pre-
potentials (Fig. 10) [43].
7.7. Gene therapy
The homozygous R33Q knock-in mouse has a dysfunctional
CASQ2, which may cause CPVT. In this mouse model, isoproterenol
induced DADs, which were markedly reduced after 12 months
following infection with an adenoviral vector (serotype 9), that
carried the normal CASQ2 gene [44]. This report suggested the
possible use of gene therapy for some types of CPVT in the future.Conﬂict of interest
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